Defunct Company
Total Trials
31
As Lead Sponsor
As Collaborator
0
Total Enrollment
12,829
NCT00610727
Staccato Prochlorperazine Single Dose PK Study
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 31, 2004
Completion: Oct 31, 2004
NCT00610428
Staccato Prochlorperazine in Migraine (in Clinic)
Phase: Phase 2
Start: Mar 31, 2005
Completion: Oct 31, 2005
NCT00444522
Staccato Alprazolam Single Dose PK
Start: Jun 30, 2005
Completion: Aug 31, 2005
NCT00444028
Staccato Loxapine Single Dose PK
Start: Sep 30, 2005
Completion: Nov 30, 2005
NCT00402350
Staccato Fentanyl Single and Multidose PK
Start: Apr 30, 2006
Completion: Nov 30, 2006
NCT00422812
Staccato Prochlorperazine in Migraine (Out Patient)
Completion: Jan 31, 2007
NCT00369577
Staccato Loxapine in Agitation (Proof of Concept)
Start: Aug 31, 2006
NCT00477451
Staccato Alprazolam in Panic Attack
Start: May 31, 2007
Completion: Apr 30, 2008
NCT00489476
Staccato Loxapine in Migraine (in Clinic)
Start: Jun 30, 2007
Completion: Dec 31, 2007
NCT00543062
Staccato Prochlorperazine Thorough QT/QTc
Start: Oct 31, 2007
NCT00555412
Staccato Loxapine Multidose PK
NCT00603980
Staccato Alprazolam Abuse Liability
Start: Jan 31, 2008
Completion: Jan 31, 2009
NCT00620620
Staccato Zaleplon Single Dose Pharmacokinetics
Start: Feb 29, 2008
Completion: Mar 31, 2008
NCT00628589
Staccato Loxapine in Agitated Patients With Schizophrenia
Phase: Phase 3
Completion: May 31, 2008
NCT00721955
Staccato Loxapine in Agitated Patients With Bipolar Disorder
Start: Jul 31, 2008
Completion: Oct 31, 2008
NCT00789360
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
Start: Nov 30, 2008
Completion: Apr 30, 2009
NCT00825500
Staccato Loxapine in Migraine (Out Patient)
Start: Jan 31, 2009
Completion: Aug 31, 2009
NCT00873769
Staccato Loxapine PK in Smokers and Nonsmokers
Start: Apr 30, 2009
Completion: Jun 30, 2009
NCT00874237
Staccato Loxapine Thorough QT/QTc Study
NCT00890175
Staccato Loxapine Pulmonary Safety in Patients With Asthma
Start: May 31, 2009
NCT00889837
Staccato Loxapine Pulmonary Safety in Patients With COPD
Start: Jun 30, 2009
NCT01854710
ADASUVE 2-dose Thorough QT/QTc Study
Phase: Phase 4
Start: May 31, 2013
Completion: Jul 31, 2013
NCT01877642
ADASUVE-Lorazepam Drug-Drug Interaction
Start: Jun 30, 2013
NCT03513549
Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder
Phase: N/A
Start: Nov 4, 2014
Completion: Sep 30, 2027
NCT02351115
Staccato Alprazolam and Photoparoxysmal Response
Start: Jan 31, 2015
Completion: Jul 31, 2016
NCT03822364
Staccato Apomorphine Single and Multi Dose PK
Start: Nov 26, 2018
Completion: Mar 26, 2019
NCT04157933
Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease
Start: Oct 16, 2019
Completion: Mar 6, 2020
NCT04200092
Staccato® Granisetron Single Dose PK
Start: Nov 4, 2019
Completion: Jan 31, 2020
NCT04327765
Staccato® Granisetron Multiple Dose PK
Start: Mar 10, 2020
Completion: Aug 15, 2020
NCT04645953
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
Start: Feb 5, 2021
Completion: Jul 26, 2022
NCT05979415
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
Start: Sep 27, 2023
Completion: Feb 28, 2024